We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+8.95%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$312M
AUM Growth
-$2.13M
Cap. Flow
-$1.57M
Cap. Flow %
-0.5%
Top 10 Hldgs %
50%
Holding
82
New
21
Increased
16
Reduced
15
Closed
29

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$9.15M
2
LEGN icon
Legend Biotech
LEGN
+$8.75M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$8.75M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$8.52M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$8.52M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$21.4M
2
RVMD icon
Revolution Medicines
RVMD
+$11.3M
3
NUVL
Nuvalent
NUVL
+$9.55M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$9.21M
5
CGON icon
CG Oncology
CGON
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.17%
2 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
1
Syndax Pharmaceuticals
SNDX
$2.02B
$22.2M 7.13%
2,372,634
+774,040
+48% +$8.52M
IMVT icon
2
Immunovant
IMVT
$8.27B
$20.8M 6.68%
1,300,860
+447,388
+52% +$6.77M
SRRK icon
3
Scholar Rock
SRRK
$6.33B
$18.7M 6%
528,115
-38,097
-7% -$1.2M
CNTA
4
DELISTED
Centessa Pharmaceuticals
CNTA
$16.6M 5.34%
1,265,672
+672,337
+113% +$8.52M
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$12.8B
$15.9M 5.12%
52,694
+11,758
+29% +$3.5M
MRUS
6
DELISTED
Merus
MRUS
$14M 4.49%
266,094
-80,662
-23% -$3.79M
ACLX
7
DELISTED
Arcellx
ACLX
$13.3M 4.26%
201,452
-72,322
-26% -$4.5M
CDTX
8
DELISTED
Cidara Therapeutics
CDTX
$13M 4.17%
+266,774
New +$6.41M
RYTM icon
9
Rhythm Pharmaceuticals
RYTM
$7.31B
$11.2M 3.58%
176,752
+142,936
+423% +$8.75M
ALKS icon
10
Alkermes
ALKS
$8.79B
$10M 3.22%
351,124
+158,772
+83% +$4.73M
DNLI icon
11
Denali Therapeutics
DNLI
$3.7B
$9.9M 3.18%
707,915
+40,837
+6% +$575K
LEGN icon
12
Legend Biotech
LEGN
$4.31B
$9.59M 3.08%
+270,144
New +$8.75M
GERN icon
13
Geron
GERN
$924M
$9.38M 3.01%
6,649,244
+5,688,937
+592% +$8.06M
ZLAB icon
14
Zai Lab
ZLAB
$2.28B
$8.76M 2.81%
250,438
+224,017
+848% +$7.37M
MLYS icon
15
Mineralys Therapeutics
MLYS
$2.39B
$8.55M 2.74%
+631,586
New +$9.15M
QURE icon
16
uniQure
QURE
$2.77B
$7.98M 2.56%
572,615
-158,424
-22% -$2.13M
ROIV icon
17
Roivant Sciences
ROIV
$24.8B
$6.78M 2.18%
601,781
-1,977,079
-77% -$21.4M
AKRO
18
DELISTED
Akero Therapeutics
AKRO
$6.23M 2%
116,779
-39,406
-25% -$1.79M
INSM icon
19
Insmed
INSM
$23.5B
$6.2M 1.99%
61,578
-25,481
-29% -$1.95M
SRZN icon
20
Surrozen
SRZN
$255M
$6.14M 1.97%
686,539
+445,713
+185% +$4.07M
WVE icon
21
Wave Life Sciences
WVE
$1.12B
$5.85M 1.88%
900,338
+810,505
+902% +$5.35M
LENZ
22
LENZ Therapeutics
LENZ
$162M
$5.39M 1.73%
+183,912
New +$5M
NUVL
23
DELISTED
Nuvalent
NUVL
$4.56M 1.47%
59,828
-130,573
-69% -$9.55M
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$4.37M 1.4%
386,790
-47
-0% -$575
VTGN icon
25
VistaGen Therapeutics
VTGN
$9.4M
$4.12M 1.32%
2,413,254
+46,700
+2% +$106K
1
2 3 4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Stempoint Capital held 82 positions worth $312M, down 0.68% from $314M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Stempoint Capital's Q2 2025 filing shows 21 new, 16 increased, 15 reduced and 29 closed positions. Its largest new stake was Mineralys Therapeutics: 631,586 shares worth $8.55M. The largest sale was Roivant Sciences, an estimated $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Stempoint Capital's largest Q2 2025 buy was Mineralys Therapeutics: 631,586 shares worth $8.55M.
  • Stempoint Capital added most to Rhythm Pharmaceuticals in Q2 2025, an estimated $8.75M increase.
  • Stempoint Capital's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $21.4M.
  • Stempoint Capital fully exited Revolution Medicines in Q2 2025, selling an estimated $11.3M.
  • Stempoint Capital's ten largest holdings make up 50% of its $312M portfolio in Q2 2025.
  • Stempoint Capital opened 21 new positions and closed 29 in Q2 2025.
  • Stempoint Capital's portfolio value fell 0.68% quarter-over-quarter to $312M.

Based on Stempoint Capital's 13F filing for Q2 2025, filed 14 Aug 2025.